STAT3 and lung carcinoma: Given the increasing evidence supporting clinical application of STAT3 inhibitors as therapeutic agents in treating various cancers [32], [33], our findings underscore the relevance of targeting STAT3 in lung cancer therapy from at least two perspectives.